M

Mangalam Drugs & Organics Limited

MANGALAM
Market snapshot · 2026-08-10 21:08 UTC

27.28

+₹0.09 (+0.33%)

MARKET CAP

₹43.18 Cr

STOCK P/E

52W HIGH

₹86.90

52W LOW

₹22.80

BOOK VALUE

₹65.12

EPS

₹-28.05

ROE

-35.23%

SECTOR

Health Care

DEBT/EQUITY

109.41

VOLUME

22,062

P/B RATIO

0.42x

PEG RATIO

Sector

Health Care

Themes

Pharmaceuticals
₹82.75₹68.01₹53.27₹38.52₹23.78VolumeAug '25Sep '25Nov '25Jan '26Mar '26Apr '26Jun '26Aug '26

AI Summary

✦ Clartha

Valuation Metrics

Forward Valuation Outlook

Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.

P/S
Strongly Undervalued

5Y Average

0.66

Current

0.19

Overvalued

0.76

Undervalued

0.56

P/B
Strongly Undervalued

5Y Average

0.58

Current

0.42

Overvalued

0.66

Undervalued

0.49

Peers & Comparison

Sector: Healthcare

No peer data available for this company.
WHY THESE PEERS

Peers are filtered to companies with market cap between 0.2x and 5.0x of the primary company.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹67 CrMar 2026

Latest net profit

₹-13 CrMar 2026

Latest EPS

₹-8.25Mar 2026

Net margin

-8.0%Mar 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26-14.0%-7.0%0.0%7.0%14.0%-25 Cr0.00 Cr25 Cr50 Cr75 Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q4 '25Q1 '26Q2 '26Q3 '26Q4 '260.00 Cr20 Cr40 Cr60 Cr80 Cr₹-9₹-6₹-3₹0₹3
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOtheradjustmentsOperatingprofitOther incomeInterestOtheradjustmentsProfitbefore taxTax & otherNet Profit-25 Cr0.00 Cr25 Cr50 Cr75 Cr

Latest reported period: Mar 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-120 Cr0.00 Cr120 Cr240 Cr360 Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

MetricMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +918782971027780897357505867
Expenses +91917990916871806362526073
Operating Profit0-3271289910-5-3-2-5
OPM %0.3%-4.0%2.7%7%11%11%11%10%14%-8%-6%-2.7%-8%
Other Income +0000000000000
Interest3333444344543
Depreciation3344444454545
Profit before tax-6-10-5041112-13-12-10-13
Tax %-22%-7%-25%-920%10%-356%-125%5%91%6%-41%0%1%
Net Profit +-4-10-4043310-14-7-10-13
EPS in Rs-2.77-6.03-2.250.322.241.691.700.880.09-8.67-4.58-6.18-8.25
Raw PDF

All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).

Shareholding Pattern

HolderJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters +50.30%50.30%35.64%35.65%35.65%
FIIs +0.53%0.11%0.13%0.32%0.11%
Public +49.16%49.57%64.22%64.03%64.24%
Others0.01%0.02%0.01%
Jun 2026
Promoters +
FIIs +
Public +

Events Timeline

Intimation Of Resignation Tendered By Ragini Chokshi & Co., Secretarial Auditor Of The Company W.E.F. 4Th August, 2026.

Aug 06, 2026PDFCompany Reports Open

Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On August 12Th, 2026 Inter Alia To Approve Un-Audited Financial Results(Standalone & Consolidated) Alongwith Limited Review Report For The Quarter Ended 30Th June, 2026.

Aug 05, 2026PDFCompany Reports Open

Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure

Jul 16, 2026PDFCompany Reports Open

Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure

Jul 15, 2026PDFCompany Reports Open

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Jul 13, 2026PDFCompany Reports Open